BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee BH, Lee DS, Cho CW, Yun SS. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. World J Surg Oncol 2019;17:143. [PMID: 31416447 DOI: 10.1186/s12957-019-1685-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen X, Lai L, Ye J, Li L. Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:740762. [PMID: 34868936 DOI: 10.3389/fonc.2021.740762] [Reference Citation Analysis]
2 Zhao X, Sun X, Jing J, Zhou H, Jin Y. Safety study of Folfox-HAIC in relieving bed restriction. Journal of Interventional Medicine 2021;4:203-7. [DOI: 10.1016/j.jimed.2021.10.003] [Reference Citation Analysis]
3 Yu X, Gao X, Mao X, Shi Z, Zhu B, Xie L, Di S, Jin L. Knockdown of FOXO6 Inhibits Glycolysis and Reduces Cell Resistance to Paclitaxel in HCC Cells via PI3K/Akt Signaling Pathway. Onco Targets Ther 2020;13:1545-56. [PMID: 32110051 DOI: 10.2147/OTT.S233031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
4 Hendi M, Mou Y, Lv J, Zhang B, Cai X. Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. Gastrointest Tumors 2021;8:145-52. [PMID: 34722467 DOI: 10.1159/000516405] [Reference Citation Analysis]
5 Su YY, Li CC, Lin YJ, Hsu C. Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. Semin Liver Dis 2021;41:263-76. [PMID: 34130338 DOI: 10.1055/s-0041-1730949] [Reference Citation Analysis]
6 Chen Z, Wang J, Lin Y. Comparison of the efficacy and safety of repeated hepatectomy and radiofrequency ablation in the treatment of primary recurrent liver cancer: a meta-analysis. World J Surg Oncol 2022;20:182. [PMID: 35668464 DOI: 10.1186/s12957-022-02649-4] [Reference Citation Analysis]
7 Qin JM. Conversion therapy for primary liver cancer: Indications and selective strategies. Shijie Huaren Xiaohua Zazhi 2021; 29(10): 501-510 [DOI: 10.11569/wcjd.v29.i10.501] [Reference Citation Analysis]
8 Xu L, Chen L, Zhang W. Neoadjuvant treatment strategies for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(12): 1550-1566 [DOI: 10.4240/wjgs.v13.i12.1550] [Reference Citation Analysis]
9 Huang Y, Zhang Z, Liao W, Hu K, Wang Z. Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study. Front Oncol 2021;11:650394. [PMID: 34408974 DOI: 10.3389/fonc.2021.650394] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]